Clinical Trials and Drug Repurposing
ClinicalTrials.gov matches, VICC Meta-Knowledgebase federated evidence, OncoKB actionability, and treatment strategy for five driver mutations.
Clinical Trials
33
18 recruiting at the 2 Nov 2026 recheck; 8 trials have a European site
Recruiting Active
18
ClinicalTrials.gov API v2 status on 2 Nov 2026 (21 at the March 2026 query)
VICC Evidence
263
From 5 databases with hits (CIViC, CGI, JAX, OncoKB, PMKB); MolecularMatch returned none
OncoKB Level 1 FDA
IDH2 R140Q
Enasidenib: FDA-approved 2017 for R/R AML with IDH2 mutation
Treatment Strategy
Backbone: Venetoclax + azacitidine with enasidenib
for the IDH2 R140Q subclone (VAF 2%). The patient is currently MRD-negative
and in full donor chimerism 35 months post-allogeneic HSCT. Treatment
considerations are for relapse contingency planning.
Actionable targets: (1) IDH2 R140Q: enasidenib (FDA-approved 2017, OncoKB Level 1). ORR 40.3%, CR 19.3% in R/R AML 21
CONTRAINDICATION: Tazemetostat (EZH2 inhibitor) is CONTRAINDICATED. EZH2 V662A is loss-of-function, not gain-of-function. Tazemetostat inhibits EZH2 catalytic activity, which is already impaired by V662A. Administering tazemetostat would further reduce H3K27me3; EZH2 loss-of-function mutations in myeloid neoplasms are associated with adverse prognosis 10
Actionable targets: (1) IDH2 R140Q: enasidenib (FDA-approved 2017, OncoKB Level 1). ORR 40.3%, CR 19.3% in R/R AML 21
[21] EM 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017)
.
NCT03728335 (enasidenib maintenance post-HSCT) matched the post-transplant
setting, but has been suspended since August 2026 (accrual goal met).
(2) PTPN11 E76Q: SHP2 inhibitors are investigational only.
TNO155 23[23] MJ 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem (2020)
has Phase I and I/II trials in solid
tumours only, none in leukemia or MDS; RMC-4550 has no registered trial
(ClinicalTrials.gov, 2 Nov 2026). The earlier
AutoDock Vina scores were computed on ligand structures that turned out
to be the wrong molecules and are superseded; the docking with
PubChem-verified structures (Boltz-2 and DiffDock 2.0, 15 Apr 2026) is
on the Molecular Docking page.
CONTRAINDICATION: Tazemetostat (EZH2 inhibitor) is CONTRAINDICATED. EZH2 V662A is loss-of-function, not gain-of-function. Tazemetostat inhibits EZH2 catalytic activity, which is already impaired by V662A. Administering tazemetostat would further reduce H3K27me3; EZH2 loss-of-function mutations in myeloid neoplasms are associated with adverse prognosis 10
[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
.
On March 9, 2026 Ipsen voluntarily withdrew tazemetostat in all indications
and markets after hematologic second cancers (mostly MDS and AML) emerged in
the SYMPHONY-1 trial, consistent with the LoF concern in myeloid settings.
IDH2 R140Q FDA
Level 1
Enasidenib (AG-221), approved 2017
PTPN11 E76Q
No myeloid trial
TNO155: solid-tumour trials only; RMC-4550: no registered trial
EZH2 V662A Blocked
CONTRA
Tazemetostat: LoF variant, inhibitor CONTRAINDICATED
DNMT3A R882H
HMA
Azacitidine/decitabine (indirect, backbone therapy)
SETBP1 G870S
No Target
PP2A activators (FTY720, DT-061) preclinical only
Drug Landscape
The drug landscape spans FDA-approved agents (enasidenib, venetoclax,
azacitidine), investigational SHP2 inhibitors (Phase I/II in solid tumours only),
and preclinical repurposing candidates (PP2A activators for SETBP1).
Of the 5 driver mutations, 1 is directly druggable with an approved drug (IDH2 R140Q),
1 has investigational inhibitors with no myeloid trial (PTPN11 E76Q),
1 has an indirect HMA-based approach (DNMT3A R882H), 1 has only preclinical
candidates (SETBP1 G870S), and 1 requires avoidance of the standard
inhibitor class (EZH2 V662A).
| Target | Drug | Mechanism | Status | Level |
|---|---|---|---|---|
| IDH2 R140Q | Enasidenib (AG-221 / Idhifa) | Selective IDH2 inhibitor — blocks 2-HG production by mutant IDH2, restores norma... | FDA Approved | Approved |
| IDH2 R140Q | Vorasidenib (AG-881) | Dual IDH1/IDH2 inhibitor — brain-penetrant, primarily studied in glioma | FDA-approved for glioma only, not AML | Phase 1 (for AML context — off-label consideration) |
| PTPN11 (SHP2) E76Q | RMC-4550 (Revolution Medicines) | Allosteric SHP2 inhibitor — locks SHP2 in autoinhibited conformation, blocks RAS... | No registered trials | Phase 1/2 |
| PTPN11 (SHP2) E76Q | TNO155 (Novartis) | Allosteric SHP2 inhibitor | Phase 1/2 | Phase 1/2 |
| PTPN11 (SHP2) E76Q | JAB-3312 (Jacobio Pharmaceuticals) | Allosteric SHP2 inhibitor | Phase 1/2 | Phase 1/2 |
| PTPN11 (SHP2) E76Q | RMC-4630 (Revolution Medicines) | Allosteric SHP2 inhibitor — clinical-grade compound from same programme as RMC-4... | Phase 1/2 | Phase 1/2 |
| DNMT3A R882H | Azacitidine (Vidaza) | Hypomethylating agent (HMA) — DNA methyltransferase inhibitor, induces hypomethy... | FDA Approved | Approved |
| DNMT3A R882H | Decitabine (Dacogen) | Hypomethylating agent — similar mechanism to azacitidine but pure deoxynucleosid... | FDA Approved | Approved |
| DNMT3A R882H | Decitabine/Cedazuridine (Inqovi) | Oral HMA — decitabine + CDA inhibitor for oral bioavailability | FDA Approved | Approved |
| SETBP1 G870S | FTY720 (Fingolimod) — PP2A activator | PP2A activating drug (PAD) — disrupts SET-PP2A interaction, reactivates PP2A tum... | FDA Approved | Preclinical (for AML) |
| SETBP1 G870S | OP449 (formerly SET antagonist peptide) | Cell-penetrating peptide that binds SET and releases PP2A from SET-mediated inhi... | Preclinical | Preclinical |
| SETBP1 G870S | DT-061 (SMAP class) | Small molecule activator of PP2A — stabilises active B56alpha-containing PP2A ho... | Preclinical | Preclinical |
| General AML N/A | Venetoclax (Venclexta) | BCL-2 inhibitor — induces apoptosis in AML cells dependent on BCL-2 for survival | FDA Approved | Approved |
| General AML N/A | Midostaurin (Rydapt) | Multi-kinase inhibitor (FLT3, KIT, PDGFR, VEGFR, PKC) | FDA Approved | Not applicable unless FLT3-mutated |
| General AML N/A | Gilteritinib (Xospata) | FLT3 inhibitor (FLT3-ITD and FLT3-TKD) | FDA Approved | Not applicable unless FLT3-mutated |
| Monosomy 7 -7 | EZH2 inhibitors (tazemetostat) — synthetic lethality concept | If monosomy 7 removes one EZH2 allele, remaining allele may be haploinsufficient... | Contraindicated here (EZH2 V662A LoF) | Preclinical |
| Monosomy 7 -7 | Allogeneic stem cell transplant | Only curative option for monosomy 7 — replaces malignant clone with donor haemat... | Standard of care | Approved (transplant) |
Table 1.Drug-target landscape for patient mutation profile. Excludes tool compounds and non-applicable agents.
Source: Compiled from DrugBank, OncoKB,
DGIdb, ClinicalTrials.gov, and published literature.
VICC Meta-Knowledgebase
Total Hits
263
Across 5 databases with hits
DNMT3A R882H
55
55 associations across CIViC, JAX, PMKB, CGI, OncoKB
IDH2 R140Q
73
73 associations, 19 variant-specific, incl. Level A enasidenib
EZH2 V662A
105
105 associations (mostly gene-level, not variant-specific)
The VICC Meta-Knowledgebase
47
[47] AH 2020
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet (2020)
federates clinical evidence across
CIViC
36[36] M 2017
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet (2017)
, CGI, JAX-CKB, OncoKB
35[35] D 2017
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017)
and PMKB; MolecularMatch was also
queried but returned no hits.
Querying all 5 patient variants yields 263 total associations
spanning predictive, diagnostic, prognostic, and therapeutic evidence.
EZH2 V662A has the most hits (105),
but all are gene-level (70) or
co-occurrence (35) annotations with
no variant-specific hit, so none describes V662A itself.
IDH2 R140Q (73 hits) carries Level A
(FDA-approved) enasidenib data; DNMT3A R882H has the most
variant-specific hits (29).
SETBP1 G870S has the sparsest evidence (6 hits), reflecting the
limited therapeutic landscape for this target.
| Gene | Variant | Total Hits | Top Source | Evidence Levels |
|---|---|---|---|---|
| DNMT3A | R882H | 55 | CIVIC (41) | B:40, A:6, D:5, C:3 |
| IDH2 | R140Q | 73 | jax (35) | A:26, B:21, C:13, D:12 |
| SETBP1 | G870S | 6 | jax (3) | D:2, C:2, A:1, B:1 |
| PTPN11 | E76Q | 24 | jax (20) | D:17, B:5, A:1, C:1 |
| EZH2 | V662A | 105 | jax (76) | D:76, A:13, C:9, B:7 |
Table 2.Per-variant evidence summary from the VICC federated knowledgebase.
Source: VICC Meta-Knowledgebase
(Wagner et al., Nat Genet, 2020). Evidence levels: A (FDA/guidelines),
B (clinical evidence), C (case reports), D (preclinical).
OncoKB Clinical Actionability
OncoKB
35
[35] D 2017
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017)
classifies IDH2 R140Q
as Level 1 (FDA-approved targeted therapy), the highest actionability
designation. Of the other 4 variants, OncoKB (AML, API query 3 Nov 2026, data v7.7)
classifies DNMT3A R882H and SETBP1 G870S as Oncogenic, PTPN11 E76Q as Likely
Neutral and EZH2 V662A as Unknown; none of the 4 has an OncoKB therapeutic level.
OncoKB therefore supports 3 of the 5 variants as oncogenic; the 5-driver
classification rests on the ACMG evidence on the Pathogenicity page.
| Gene | Variant | Oncogenicity | Effect | Highest Level | Drug |
|---|---|---|---|---|---|
| EZH2 | V662A | Unknown | Unknown | None | No targeted therapy |
| DNMT3A | R882H | Oncogenic | Loss-of-function | None | No targeted therapy |
| SETBP1 | G870S | Oncogenic | Gain-of-function | None | No targeted therapy |
| PTPN11 | E76Q | Likely Neutral | Likely Neutral | None | No targeted therapy |
| IDH2 | R140Q | Oncogenic | Switch-of-function | Level 1 | Enasidenib |
Table 3.OncoKB clinical actionability annotations for all 5 patient variants.
Source: OncoKB (Chakravarty et al., JCO PO, 2017).
Tumor type context: Acute Myeloid Leukemia.
Level 1: FDA-approved. The other 4 variants have no OncoKB level.
Matched Clinical Trials
33 clinical trials matched the patient's mutation profile via the
ClinicalTrials.gov API v2 (query of 27 Mar 2026). At the status recheck on
2 Nov 2026, 18 are recruiting (21 in March).
Trials are scored by eligibility criteria overlap with the patient's
specific mutations, diagnosis (MDS-AML), age (36), and post-HSCT status.
The highest-scored trial is NCT03383575 (azacitidine +
enasidenib for IDH2-mutant MDS, score 100). The most directly relevant
for current status was NCT03728335 (enasidenib maintenance
post-allogeneic HCT in IDH2-mutant patients, score 88), now suspended
(accrual goal met, August 2026).
| NCT ID | Title | Phase | Status | Target | Score |
|---|---|---|---|---|---|
| NCT03383575 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic... | Ph 2 | Recruiting | IDH2 R140Q | 100 |
| NCT06387069 | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid ... | Ph 3 | Recruiting | IDH2 R140Q | 99 |
| NCT04603001 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With ... | Ph 1 | Active | IDH2 R140Q | 96 |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation... | Ph 1 | Active | IDH2 R140Q | 92 |
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | Ph 2 | Active | IDH2 R140Q | 91 |
| NCT04774393 | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enaside... | Ph 1, PHASE2 | Recruiting | IDH2 R140Q | 91 |
| NCT03728335 | Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutati... | Ph 2 | SUSPENDED | IDH2 R140Q | 88 |
| NCT05010772 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or... | Ph 1 | Recruiting | IDH2 R140Q + combination therapy | 88 |
| NCT06577441 | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedaz... | Ph 2 | Recruiting | IDH2 R140Q | 85 |
| NCT05441514 | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refr... | Ph 1 | COMPLETED | IDH2 R140Q | 85 |
| NCT06377579 | OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute... | Not specified | Recruiting | IDH2 R140Q | 84 |
| NCT06611839 | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed ID... | Ph 1, PHASE2 | Recruiting | IDH2 R140Q | 83 |
Table 4.Top 12 matched clinical trials ranked by eligibility score. Status as of 2 Nov 2026. NCT IDs link to ClinicalTrials.gov.
Source: ClinicalTrials.gov API v2.
Queried: IDH2 AML, SHP2 myeloid, venetoclax + azacitidine + IDH2,
PTPN11 leukemia, MDS monosomy 7, enasidenib combinations.
Eligibility scores incorporate mutation match, diagnosis, age, and HSCT status.
References
- Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017). DOI
- Chase A, Score J, Lin F, et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020). DOI
- LaMarche MJ et al. Identification of TNO155, an allosteric SHP2 inhibitor for cancer therapy. J Med Chem (2020). DOI
- Chakravarty D et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017). DOI
- Wagner AH et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet (2020). DOI
- Griffith M et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet (2017). DOI
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function. J Comput Chem (2010). DOI